Clene Inc.CLNN
What Clene Inc. does.
We are a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (“CSN ® ”) therapeutics. CSN ® therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities not present in those same elements in bulk form. These catalytic activities drive, support, and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed, and damaged cells.
We believe that our patent-protected, proprietary position affords us the potential to develop a broad and deep pipeline of novel CSN therapeutics to address a range of diseases with high impact on human health. We innovated an electro-crystal-chemistry drug development platform that draws from advances in nanotechnology, plasma and quantum physics, materials science, and biochemistry. Our platform process results in nanocrystals with faceted structures and surfaces that are free of the chemical surface modifications that accompany other production methods. Many traditional methods of nanoparticle synthesis involve the unavoidable deposition of potentially toxic organic residues and stabilizing surfactants on the particle surfaces. Synthesizing stable nanocrystals that are both nontoxic and highly catalytic has overcome this significant hurdle in harnessing transition metal catalytic activity for therapeutic use. Our clean-surfaced nanocrystals exhibit catalytic activities many-fold higher than other commercially available nanoparticles, produced using various techniques, that we have comparatively evaluated.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $206,000 | $723,000 | $473,000 | $654,000 | $342,000 | $200,000 |
| Net income | -$19.3M | -$9.7M | -$29.9M | -$49.5M | -$39.4M | -$26.2M |
| Free cash flow | -$19.3M | -$36.0M | -$44.2M | -$30.5M | -$21.3M | -$18.6M |
More on CLNN.
- Clene Inc. summary
- Clene Inc. financial statements
- Clene Inc. key metrics
- Clene Inc. health scores and style box
- Clene Inc. earnings
- Clene Inc. dividends
- Clene Inc. valuation
- Clene Inc. ownership and insiders
- Clene Inc. peers
Figures from Clene Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.